McDonald J, et al. - Researchers compared the effectiveness and safety of oral and transdermal rivastigmine for postural instability in patients with Parkinson disease dementia (PDD) who were candidates for a cholinesterase inhibitor. The change in mean velocity of the center of pressure (CoP) after 6 months was the primary outcome. Structural parameters of dynamic posturography, clinical rating scales, and adverse events requiring dose reduction were the included secondary outcomes. Results of this study suggested that rivastigmine could improve certain elements of postural control, notably the mean velocity of CoP. Data reported that benefits appear to be more obvious under more taxing sensory conditions.